The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials
Roofeh, D., Lescoat, A., & Khanna, D. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1836156 · Cited by 12
Ianni, A., Hofmann, M., Kumari, P., Tarighi, S., Al-tamari, H. M., Görgens, A., Giebel, B., Nolte, H., Krüger, M., Salwig, I., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639162 · Cited by 12
Geroldinger‐Simić, M., Bögl, T., Himmelsbach, M., Sepp, N. T., & Buchberger, W. W. (2021) · Diagnostics · doi:10.3390/diagnostics11112116 · Cited by 12
An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis
Mateos‐Toledo, H., Mejía, M. E., Rodríguez-Barreto, Ó., Mejía-Hurtado, J. G., Rojas‐Serrano, J., Estrada, A., Castillo-Pedroza, J., Castillo-Castillo, K., Gaxiola, M., Buendía-Roldán, I., et al. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.08.008 · Cited by 12
Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know
Joerns, E. K., Adams, T. N., Sparks, J. A., Newton, C. A., Bermas, B. L., Karp, D. R., & Makris, U. E. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01072-8 · Cited by 14
Sun, K., Fisher, J. H., & Pagnoux, C. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01078-2 · Cited by 12
Campochiaro, C., Lazzaroni, M. G., Bruni, C., Zanatta, E., Luca, G. D. D., & Matucci‐Cerinic, M. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221116408 · Cited by 13
Ilg, M. M., Lapthorn, A. R., Ralph, D. J., & Cellek, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277646 · Cited by 12
Scheidegger, M., Boubaya, M., Garaiman, A., Barua, I., Becker, M. O., Bjørkekjær, H. J., Bruni, C., Dobrota, R. D., Fretheim, H., Jordan, S., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2023-003658 · Cited by 12
Self-citationRatanawatkul, P., Solomon, J. J., Kim, D., George, M. P., McGibbon, L. R. M., Demoruelle, M. K., Maleki-Fischbach, M., Amigues, I., Kastsianok, L., & Pérez, E. R. F. (2020) · ERJ Open Research · doi:10.1183/23120541.00309-2019 · Cited by 12
Mihai, C., Dobrota, R. D., Assassi, S., Mayes, M. D., & Distler, O. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11165 · Cited by 12
Self-citationKuwana, M., & Distler, O. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320902551 · Cited by 12
Self-citationChaaban, S., & Sadikot, R. T. (2023) · Pathogens · doi:10.3390/pathogens12030464 · Cited by 11
Ghincea, A., Woo, S., Yu, S., Pivarnik, T., Fiorini, V., Herzog, E. L., & Ryu, C. (2023) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-023-00211-1 · Cited by 11
Heyne, S., Haufe, E., Beissert, S., Schmitt, J. M., & Günther, C. (2023) · Acta Dermato Venereologica · doi:10.2340/actadv.v103.6502 · Cited by 11
Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease
Mulcaire-Jones, E., Pugashetti, J. V., Oldham, J. M., & Khanna, D. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786155 · Cited by 11
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study
Luca, G. D. D., Lorenzis, E. D., Campochiaro, C., Cacciapaglia, F., Papa, N. D., Zanatta, E., Airó, P., Lazzaroni, M. G., Giuggioli, D., Santis, M. D., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae280 · Cited by 11
Yamaguchi, T., Shimizu, J., Shigematsu, F., Watanabe, N., Hasegawa, T., Horio, Y., Inaba, Y., & Fujiwara, Y. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-45 · Cited by 11
Madsen, S. F., Madsen, S., Madrid, A. S., Andersen, M. R., Bay‐Jensen, A., & Thudium, C. S. (2024) · Translational Medicine Communications · doi:10.1186/s41231-024-00180-0 · Cited by 11
Papa, N. D., Cavalli, S., Rindone, A., Onida, F., Saporiti, G., Minniti, A., Pellico, M. R., Iannone, C., Trignani, G., D’Angelo, N., et al. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03408-4 · Cited by 11
Yu, S., Hu, B., Sun, Y. S., Peng, X. Y., Lee, C., Woo, S., McGovern, J., Zielonka, J., Saber, T., Ghincea, A., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.01564-2024 · Cited by 12
Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review
Montero, I. E., Hernández‐González, F., & Sellarés, J. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00302-5 · Cited by 11
Current State of Fibrotic Interstitial Lung Disease Imaging
Chelala, L., Brixey, A. G., Hobbs, S., Kanne, J. P., Kligerman, S. J., Lynch, D. A., & Chung, J. H. (2025) · Radiology · doi:10.1148/radiol.242531 · Cited by 11
Jarnagin, H. C., Parvizi, R., Gong, Z., Gedert, R. J., Xing, X., Tsoi, L. C., Wasikowski, R., Morrisson, M. J., Perreard, L., Pioli, P. A., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.198954 · Cited by 11
Gale, S. L., Trinh, H., Mathew, N., Jahreis, A., Lin, C. J. F., & Sarsour, K. (2019) · Rheumatology and Therapy · doi:10.1007/s40744-019-00181-8 · Cited by 11
Vicente‐Rabaneda, E. F., López-Matencio, J. M. S., Ancochea, J., Blanco, R., González-Gay, M. Á., & Castañeda, S. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1973428 · Cited by 11
Kurosaki, T., Kanda, H., Hashizume, J., Sato, K., Harasawa, H., Nakamura, T., Sasaki, H., & Kodama, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111983 · Cited by 11
Castelino, F. V., VanBuren, J. M., Startup, E., Assassi, S., Bernstein, E. J., Chung, L. S., Correia, C. S., Evnin, L. B., Frech, T., Gordon, J., et al. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14253 · Cited by 11
Kreuter, M., Maher, T. M., Corte, T. J., Molina‐Molina, M., Axmann, J., Gilberg, F., Kirchgaessler, K.-U., & Cottin, V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02009-w · Cited by 11
Self-citationZanin-Silva, D. C., Santana-Gonçalves, M., Vasconcelos, M., Lima-Júnior, J. R., Dias, J. B. E., Moraes, D. A., Covas, D. T., Malmegrim, K. C. R., Ramalho, L. N. Z., & Oliveira, M. C. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02779-w · Cited by 11
Pregnancy Considerations for Patients With Interstitial Lung Disease
Grant-Orser, A., Metcalfe, A., Pope, J. E., & Johannson, K. A. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.024 · Cited by 11
Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis
Porse, S., Hoyer, N., & Shaker, S. B. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.107015 · Cited by 12
Fritzler, M. J., Bentow, C., Beretta, L., Palterer, B., Perurena-Prieto, J., Sanz-Martínez, M. T., del Castillo, A. G., Marín, A., Fonollosa‐Pla, V., Callejas-Moraga, E. L., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13071257 · Cited by 11
Volkmann, E. R., McMahan, Z. H., Smith, V. M., Jouneau, S., Miede, C., Alves, M., Herrick, A. L., & the SENSCIS Trial Investigators (2023) · Arthritis Care & Research · doi:10.1002/acr.25176 · Cited by 12
Self-citationLøkke, A., Castello, L., Martins, P. P., Soulard, S., & Hilberg, O. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02701-z · Cited by 12
Superiority of systemic bleomycin to intradermal HOCl for the study of interstitial lung disease
Morozan, A., Joy, S., Fujii, U., Fraser, R. S., Watters, K. A., Martin, J. G., & Colmegna, I. (2023) · Scientific Reports · doi:10.1038/s41598-023-47083-y · Cited by 11
Battista, M. D., Sedie, A. D., Romei, C., Tavanti, L. M., Rio, M. D., Morganti, R., Rossa, A. D., & Mosca, M. (2023) · Rheumatology · doi:10.1093/rheumatology/kead642 · Cited by 11
Gregory, K., Hansen, D., Penglase, R., Apostolopoulos, D., Ngian, G., Stevens, W., Morrisroe, K., Ferdowsi, N., Ross, L., Walker, J. G., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42850 · Cited by 11
Liakouli, V., Ciaffi, J., Ursini, F., Ruscitti, P., Melicòni, R., Ciccia, F., Cipriani, P., & Giacomelli, R. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1813569 · Cited by 11
Volkmann, E. R., Steen, V. D., Li, N., Roth, M. D., Clements, P. J., Furst, D. E., Assassi, S., Khanna, D., Kim, G. H. J., Goldin, J. G., et al. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11206 · Cited by 11
Hoffmann‐Vold, A., Fretheim, H., Sarna, V. K., Barua, I., Carstens, M. N., Distler, O., Khanna, D., Volkmann, E. R., Midtvedt, Ø., Didriksen, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048541 · Cited by 11
Self-citationChronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Amubieya, O., Ramsey, A. L., Derhovanessian, A., Fishbein, G. A., Lynch, J. P., Belperio, J. A., & Weigt, S. S. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1729175 · Cited by 11
Bruni, C., Campochiaro, C., & Vries-Bouwstra, J. K. D. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.01.005 · Cited by 11
Cassone, G., Sebastiani, M., Vacchi, C., Cerri, S., Salvarani, C., & Manfredi, A. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101051 · Cited by 11
Recent advances in the management of systemic sclerosis-associated interstitial lung disease
Hoffmann‐Vold, A., Distler, O., Crestani, B., & Antoniou, K. M. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000901 · Cited by 11
Self-citationBarešić, M., Novak, S., Perković, D., Karanović, B., Mirić, F., Radić, M., & Anić, B. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06689-3 · Cited by 10
Liao, Y.-W., Liu, M.-C., Wu, Y., Hsu, C., Huang, W., Chen, Y., & Fu, P. (2024) · European journal of medical research · doi:10.1186/s40001-024-01673-2 · Cited by 10
Connective Tissue Disease Associated Interstitial Lung Disease
Matson, S. M., & Demoruelle, M. K. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.03.001 · Cited by 11
Lorenzis, E. D., Galdo, F. D., Natalello, G., Varone, F., Donato, S. D., Verardi, L., Calandriello, L., Kakkar, V., Cerasuolo, P. G., Larici, A. R., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2153oc · Cited by 11
CAR-T cell therapy in rheumatic diseases: a review article
Patil, H., Bharadwaj, R. K., Dutta, N., Ramaswamy, S., Prasad, B. S., & Mamadapur, M. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07451-7 · Cited by 11
Hanif, I., Assassi, S., Mayes, M. D., McMahan, Z. H., Zhang, M., Charles, J., VanBuren, J. M., Alvey, J. S., Ghaffari, K., Bernstein, E. J., et al. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43237 · Cited by 10
Self-citationSystemic sclerosis-associated interstitial lung disease
Scallan, C. J., Collins, B. F., & Raghu, G. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000707 · Cited by 10
Self-citationFu, Y., Gong, T., Tsauo, J., Sang, M., Zhao, H., Zhang, X., Li, J., & Li, X. F. (2021) · Surgery · doi:10.1016/j.surg.2021.03.055 · Cited by 10
Roofeh, D., Barratt, S. L., Wells, A. U., Kawano-Dourado, L. B., Tashkin, D. P., Strand, V., Seibold, J. R., Proudman, S., Brown, K. K., Dellaripa, P. F., et al. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.08.001 · Cited by 10
Zhou, Y., Zhang, Y., Cheng, H., Li, X., Feng, D., Yue, S., Xu, J., Xie, H., & Luo, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10112715 · Cited by 10
Inoue, Y., Wells, A. U., Song, J. W., Xu, Z., Kitamura, H., Suda, T., Okamoto, M., Müller, H., Coeck, C., Rohr, K. B., et al. (2023) · Respirology · doi:10.1111/resp.14452 · Cited by 10
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 10
Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease
Berger, K., & Kaner, R. J. (2023) · Life · doi:10.3390/life13030599 · Cited by 10
Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?
Campochiaro, C., Allanore, Y., Braun‐Moscovici, Y., Matucci‐Cerinic, M., & Balbir‐Gurman, A. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103439 · Cited by 10
Binda, M., Moccaldi, B., Civieri, G., Cuberli, A., Doria, A., Tona, F., & Zanatta, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042299 · Cited by 10
Emerging therapeutic targets in systemic sclerosis
O’Reilly, S. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02424-w · Cited by 10
Systemic sclerosis (scleroderma)
Assassi, S., & Varga, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00015-1 · Cited by 10
Oxygen for interstitial lung diseases
Khor, Y. H., Smith, D. J. F., Johannson, K. A., & Renzoni, E. A. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000691 · Cited by 11
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib
Ameri, P., Tini, G., Spallarossa, P., Mercurio, V., Tocchetti, C. G., & Porto, I. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14793 · Cited by 10
Lescoat, A., Roofeh, D., Townsend, W. A., Hughes, M., Sandler, R. D., Zimmermann, F., Pauling, J. D., Buch, M. H., & Khanna, D. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044765 · Cited by 10
Lang, D., Akbari, K., Horner, A., Hepp, M., Kaiser, B., Pieringer, H., & Lamprecht, B. (2021) · Lung · doi:10.1007/s00408-021-00434-w · Cited by 10
Jacquerie, P., Henket, M. A., André, B., Moermans, C., de Seny, D., Gester, F., Louis, R. E., Malaise, M., & Guiot, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87701-1 · Cited by 10
Caetano, J., Batista, F., Amaral, M., Oliveira, S., & Alves, J. D. (2021) · Rheumatology International · doi:10.1007/s00296-021-04983-4 · Cited by 10
Shirai, Y., Fukue, R., Kaneko, Y., & Kuwana, M. (2021) · Diagnostics · doi:10.3390/diagnostics11112007 · Cited by 10
Self-citationTherapeutic molecular targets of SSc-ILD
Zhang, Y., & Distler, J. H. W. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319899013 · Cited by 12
Yanagihara, T., Scallan, C. J., Ask, K., & Kolb, M. R. J. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2006186 · Cited by 10
Schinke, S., & Riemekasten, G. (2019) · Der Internist · doi:10.1007/s00108-019-00699-7 · Cited by 10
Huang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01559-7 · Cited by 10
Maher, T. M., BOURDIN, A. A., Volkmann, E. R., Vettori, S., Distler, J. H. W., Alves, M., Stock, C., & Distler, O. (2022) · Respiratory Research · doi:10.1186/s12931-022-02095-6 · Cited by 9
Self-citationCereser, L., Marchesini, F., Poi, E. D., Quartuccio, L., Zabotti, A., Zuiani, C., & Girometti, R. (2022) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2022.21488 · Cited by 9
Systemic Sclerosis-Associated Myopathy: How to Treat
Selva-O’Callaghan, A., del Castillo, A. G., Gil‐Vila, A., Araguás, E. T., Matas-García, A., Milisenda, J. C., Pinal‐Fernandez, I., & Simeón‐Aznar, C. P. (2023) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-023-00206-y · Cited by 9
Mechanisms and management of cough in interstitial lung disease
Rasheed, A., Metersky, M. L., & Ghazal, F. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2299751 · Cited by 9
Costa, E., Pedroso, A. R., Matos, R., Rodrigues, M. C., Padrão, E. F. D. S. A. D., Sousa‐Neves, J., & Rolo, R. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107603 · Cited by 9
Stamm, L., Garaiman, A., Becker, M. O., Bruni, C., Dobrota, R. D., Elhaï, M., Ismail, S., Jordan, S., Zampatti, N., Tatu, A. M., et al. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004333 · Cited by 9
Self-citationTakada, T., Aoki, A., Shima, K., & Kikuchi, T. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.11.003 · Cited by 9
Volkmann, E. R., Assassi, S., Denton, C. P., Simonovska, R., Sambevski, S., Alves, M., & Bernstein, E. J. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2024-1063 · Cited by 9
Self-citationGuo, Y., Wang, Q., Zhang, Y., Ren, L., Wang, Y., Liu, Y., Liu, M., Tian, X., Liu, Q., Chen, Y., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.01667-2024 · Cited by 9
Khor, Y. H., Moor, C. C., Merkt, W., Buschulte, K., Zheng, B., Müller, V., & Kreuter, M. (2025) · European Respiratory Review · doi:10.1183/16000617.0046-2025 · Cited by 9
A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score
Bruni, C., Tofani, L., Fretheim, H., Liem, S. I. E., Velauthapillai, A., Bjørkekjær, H. J., Barua, I., Galetti, I., Garaiman, A., Becker, M. O., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf445 · Cited by 9
Self-citationDiagnosis and Management of Interstitial Lung Disease in Patients with Connective Tissue Diseases
Koslow, M., Maleki-Fischbach, M., & Keith, R. C. (2021) · Case Reports in Rheumatology · doi:10.1155/2021/6677353 · Cited by 9
New risk model is able to identify patients with a low risk of progression in systemic sclerosis
van Leeuwen, N. M., Maurits, M. P., Liem, S. I. E., Ciaffi, J., Marsan, N. A., Ninaber, M. K., Allaart, C. F., Dongen, H. G.-V., Goekoop, R. J., Huizinga, T. W. J., et al. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001524 · Cited by 9
Hoa, S. A.-T., Baron, M. G., & Hudson, M. (2021) · Rheumatology · doi:10.1093/rheumatology/keab929 · Cited by 9
Hayashi, S., Matsubara, T., Fukuda, K., Maeda, T., Funahashi, K., Hashimoto, M., Takashima, Y., Kikuchi, K., Fujita, M., Matsumoto, T., et al. (2022) · Rheumatology Advances in Practice · doi:10.1093/rap/rkac088 · Cited by 9
Blank, N., Schmalzing, M., Moinzadeh, P., Oberste, M., Siegert, E., Müller‐Ladner, U., Riemekasten, G., Günther, C., Kötter, I., Zeidler, G., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02948-x · Cited by 9
Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice
Enomoto, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315027 · Cited by 9
Nakshbandi, G., Moor, C. C., Antoniou, K. M., Cottin, V., Hoffmann‐Vold, A., Koemans, E. A., Kreuter, M., Molyneaux, P. L., Wuyts, W. A., & Wijsenbeek, M. S. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02336-4 · Cited by 10
Connective Tissue Disease Associated Interstitial Lung Disease
Matson, S. M., & Demoruelle, M. K. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.005 · Cited by 9
Functional roles of CD26 / DPP4 in bleomycin‐induced pulmonary fibrosis
Koyanagi, Y., Kawasaki, T., Kasuya, Y., Hatano, R., Sato, S., Takahashi, Y., Ohnuma, K., Morimoto, C., Dudek, S. M., Tatsumi, K., et al. (2023) · Physiological Reports · doi:10.14814/phy2.15645 · Cited by 9
Liao, Y.-W., Chen, Y., Liu, M.-C., Wu, Y., Hsu, C., Fu, P., Huang, W., & Chen, Y. (2024) · European journal of medical research · doi:10.1186/s40001-024-01644-7 · Cited by 9
Maher, T. M., Brown, K. K., Cunningham, S., DeBoer, E. M., Deterding, R. R., Fiorino, E. K., Griese, M., Schwerk, N., Warburton, D., Young, L. R., et al. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26882 · Cited by 9
Self-citationLi, Y., Huang, H., Ye, X., Zeng, B., Huang, F., & Chen, L. L. (2024) · Medicine · doi:10.1097/md.0000000000037808 · Cited by 9
Fan, J., Chang, Y., Cheng, S., Liang, B., & Qu, D. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03679-z · Cited by 9
Panopoulos, S., Tzilas, V., Bournia, V.-K., Tektonidou, M. G., & Sfikakis, P. P. (2024) · Rheumatology International · doi:10.1007/s00296-024-05695-1 · Cited by 9
Unraveling the role of MiR ‐181 in skin fibrosis pathogenesis by targeting NUDT21
Mills, T., Wu, M., Alonso, J., Puente, H., Charles, J., Chen, Z., Yoo, S. H., Mayes, M. D., & Assassi, S. (2024) · The FASEB Journal · doi:10.1096/fj.202400829r · Cited by 9
Self-citationSystemic sclerosis-associated interstitial lung disease: How to manage in 2024?
Bautista-Sanchez, R., & Khanna, D. (2024) · Rheumatology and Immunology Research · doi:10.2478/rir-2024-0022 · Cited by 9
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
